Table 1. Best reported survival with CRS/HIPEC compared to systemic therapy.
Cancer | IP therapy | Median survival (months) |
References | |
---|---|---|---|---|
IP therapy | Systemic therapy | |||
Appendiceal | CRS/HIPEC ± EPIC | 196 | 117.6* | (1,29) |
Colorectal | CRS/HIPEC ± EPIC | 62.7 | 23.9 | (30) |
Mesothelioma | CRS/HIPEC ± EPIC | 92 | 12.1 | (31,32) |
*, iterative CRS alone. CRS, cytoreductive surgery; HIPEC, hyperthemic intraperitoneal chemoperfusion; EPIC, early postoperative chemoperfusion.